View Author
patient methylation glioblastoma cancer model gefitinib response tumor treatment analysis tissue study sample survival chemotherapy probe status expression fication sarcoma glioma promoter value classi group trial pathway tumour outcome surgery dataset methylated mgmt methylation table classi fication prediction mgmt promoter methylation radiotherapy mgmt-stp grade association factor oncol therapy tissue sarcomas mgmt methylation status -450k probability amplification mgmt-stp 27 methylation status mpnst hm -450k effect research month receptor phase university prognostic 1.0 0.0 0.8 resection mgmt-stp 27 model gefitinib treatment 0.6 0.4 0.2 mgmt promoter concentration island growth phospho-protein phosphorylation tumor tissue department synovial sarcoma region anaplastic
3 Most Recent Publications
|
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status
(Article)
Bady, P. Sciuscio, D. Mcdonald, D.R. Lacombe, D. Stupp, R. Delorenzi, M. Hegi, M.E. Diserens, A.C. Bloch, J. Bent, M.J. van den Marosi, C. Dietrich, P-Y. Weller, M. Mariani, L. Heppner, F.L. |
2012-10-01
|
|
Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib - A phase II trial
(Article)
Hegi, M.E. Diserens, A.C. Heppner, F. Yonekawa, Y. Merlo, A. Frei, K. Mariani, L. Hofer, S. Bady, P. Kamoshima, Y. Kouwenhoven, M.C.M. Delorenzi, M. Lambiv, W.L. Hamou, M.F. Matter, M.S. Koch, A. |
2011-06-01
|
|
Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: Results of a pooled analysis from United States and European groups
(Article)
Ferrari, A. Miceli, R. Salvo, G.L.D. Casanova, M. Vannoesel, M.M. Kelsey, A. Stevens, M.C. Devidas, M. Pappo, A.S. Spunt, S.L. Rey, A. Oberlin, O. Orbach, D. Brennan, B. Mariani, L. Carli, M. Bisogno, G. Cecchetto, G. |
2011-03-01
|
